Lamotrigin ”Nordic Prime 100 mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
114	非ジストロフィー性ミオトニー症候群	1

114. 非ジストロフィー性ミオトニー症候群

---

臨床試験数 : 13 /  薬物数 : 19 - (DrugBank : 5) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 10

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-003784-94-DK (EUCTR)	20/01/2022	30/11/2021	Which treatment are the best to reduce myotonia?	Treatment of Myotonia - Lamotrigine versus Namuscla	Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, and Hyperkalemic periodic paralysis MedDRA version: 20.1;Level: LLT;Classification code 10049841;Term: Myotonia congenital;System Organ Class: 100000004850 MedDRA version: 20.1;Classification code 10076440;Term: Hyperkalemic periodic paralysis;System Organ Class: 100000004850;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Trade Name: Namuscla INN or Proposed INN: Mexiletine Trade Name: Lamotrigin ”Nordic Prime 25 mg INN or Proposed INN: LAMOTRIGINE Trade Name: Lamotrigin ”Nordic Prime 50 mg INN or Proposed INN: LAMOTRIGINE Trade Name: Lamotrigin ”Nordic Prime 100 mg INN or Proposed INN: LAMOTRIGINE	Rigshospitalet, department of Neurology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32	Phase 3	Denmark